Analysis by Product Type (ELISA Assay Kits, Immunoassay Kits, and Others); by Assay Type (Anti-Asthma, and Bronchodilator); and by End-User (Hospitals, Diagnostic Laboratories, and Research Centers & Academic Institutes) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now
The global anti-asthma TDM assay kits market is estimated to garner a revenue of USD 32 Billion by the end of 2035 by growing at a CAGR of ~6% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of USD 18 Billion in the year 2022. The growth of the market can be attributed to the escalating cases of asthma worldwide. TDM is used to measure the plasma concentration of the drug in the given therapy, and it involves measuring drug concentration and clinical interpretation of the result. Asthma is thought to affect at least 300 million individuals worldwide, 30 million of whom reside in mainland China.
In addition to these, factors that are believed to fuel the market growth of anti-asthma TDM assay kits include the rise in the consumption of tobacco. Scientists claim that tobacco smoke is a common trigger for asthma. The smoke from tobacco products, such as cigars, cigarettes, or pipes can aggravate the condition. The data released by the World Health Organization states that in 2020, 22.3% of the world population used tobacco. On account of excessively increasing tobacco users, the global anti-asthma TDM assay kits market is estimated to grow during the forecast period. Also, the worsening air quality is causing various respiratory diseases and asthma is the most common of all. This is also estimated to fuel the global anti-asthma TDM assay kits market growth during the forecast period. The World Health Organization (WHO) estimates that, as of 2019, 99% of the world's population resided in areas where the WHO's air quality standards were not being met. According to data from the same year, more than 90% of individuals worldwide lived in regions where PM2.5 concentrations were higher than the WHO annual air quality criteria (AQG), which are 10 g/m3.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 18 Billion |
|
Forecast Year Market Size (2035) |
~ USD 32 Billion |
|
Regional Scope |
|
Growth Drivers
Rising Cases of Asthma – Growing cases of asthma are expected to boost the demand for anti-asthma TDM assay kits. In the US, 25 million people suffer from asthma. This equates to about 1 in every 13 people. Over 20 million Americans age 18 and over suffer from asthma.
Increasing Concentration of Pollutants in the Air– As per the data of the Environmental Protection Agency, between the years 1990-2020, the level of concentration of carbon monoxide and nitrogen increased by 73% and 61%, respectively. Moreover, the emission of sulfur dioxide increased by 91%, and the concentration of ozone and coarse particulate matter leveled up by 25% and 26%, respectively.
Growing Demand for Medical Precaution for Asthma – Diagnostic test can help the patient to know the severity of the issue and asthma & COPD drugs can help to even prevent it. Over the previous four years, sales of anti-asthma medications have increased by over 50% throughout the nation.
Rising Investment in Medicines for Asthma– The British pharmaceutical, AstraZeneca is investing about USD 77 million to increase respiratory drug production at its Sydney facility. This facility is expected to fulfill the rising demand in China for anti-asthmatic drugs.
Challenges
The global anti-asthma TDM assay kits market is segmented and analyzed for demand and supply by product type into ELISA assay kits, immunoassay kits, and others. Out of the three types of products, the ELISA assay kits segment is estimated to gain the largest market share over the projected time frame. The enzyme-linked immunosorbent assay, or ELISA test, quantifies the quantity of allergen-specific antibodies in our body. The growth of the segment can be attributed to the rise in the number of variants of ELISA test kits manufactured in the market. For instance, a leading manufacturer of China, Wuhan Fine Biotech Co., Ltd. currently have more than 7600 types of ELISA kits in the market.
The global anti-asthma TDM assay kits market is also segmented and analyzed for demand and supply by end-user in hospitals, diagnostic laboratories, research centers & academic institutes. Amongst these three segments, the hospital segment is expected to garner a significant share. Patients suffering from asthma often visit hospitals for treatment, and Acute asthma attacks continue to be a common reason for ER visits and hospital admissions. In 2018, around 6 million asthma patients visited hospitals for treatment. Moreover, in the same year, around 180,000 people were discharged from hospital inpatient care and nearly 2 million asthmatic patients were released from the hospital's emergency department. Furthermore, asthma-related visits to the emergency room are approximately five times as common among black Americans than among white Americans.
Our in-depth analysis of the global anti-asthma TDM assay kits market includes the following segments:
|
By Product Type |
|
|
By Assay Type |
|
|
By End User |
|
The North American anti-asthma TDM assay kits market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing count of patients suffering from asthma. A recent report published by the Asthma and Allergy Foundation of America states that approximately 25 million people living in the United States have asthma. On the other hand, the deteriorating quality of air in the region is expected to boost the market growth in the region. Research by the American Lung Association found that more than 135 million Americans breathe toxic air, putting their health and lives in danger.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: The rising cases of asthma, rising air pollution, and growing demand for anti-asthma drugs are expected to be the major factor driving the growth of the global anti-asthma TDM assay kits market during the forecast period.
Ans: The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 – 2035.
Ans: Lack of awareness regarding anti-asthma TDM assay kits, and there are very less skilled workers present to perform this test are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences, Inc., Merck KGaA, Elabscience Biotechnology Inc., MyBioSource Inc., Creative Diagnostics, Diagnostic Automation (Cortez Diagnostics, Inc.), and F. Hoffmann-La Roche Ltd.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product type, assay type, end user, and by region.
Ans: The ELISA assay kits segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
